Repligen (RGEN) Stock: Buy, Sell, or Hold?
$172.62
-1.36 (-0.78%)
âŧ
5d:
-3.13%
30d:
-1.6%
90d:
+3.06%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (81%)
Quality Score
49/100
Position
SLIGHTLY LOW
30-Day Fair Range
$171.17 â $182.34
Position: SLIGHTLY LOW
Forward P/E & Valuation
65.1x
FAIR
vs 60.7x historical avg
Wall Street Target
$203.21
+17.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$168.03 / $191.05
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 2.3% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.11
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$80.17
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $172.62, which is considered slightly low relative to its 30-day fair value range of $171.17 to $182.34. The stock's valuation (Forward PE: 65.1) is in line with its historical norms (60.7). At these levels, the market is pricing in 2.3% annual earnings growth.
Technical Outlook: Technically, RGEN is in a strong uptrend. The price is currently testing key support at $168.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $203.21 (+17.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong uptrend. The price is currently testing key support at $168.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $203.21 (+17.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$171.17 -
$182.34
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
Trading Range & Key Levels
30-Day Trading Range
$171.17 -
$182.34
Current vs Trading Range
SLIGHTLY LOW
Support Level
$168.03
Resistance Level
$191.05
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($203.21)
- BULLISH: Expecting earnings turnaround to 2.3% growth with 10.9% revenue growth
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
65.09
Wall Street Target
$203.21
(+17.7%)
Revenue Growth (YoY)
10.9%
Earnings Growth (YoY)
-65.9%
Profit Margin
-1.5%
Valuation Premium vs History
+2.3% premium
PE vs Historical
65.1 vs 60.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.3%
(market-implied from PE analysis)
1-Year Target
$176.59
(+2%)
2-Year Target
$180.65
(+5%)
3-Year Target
$184.81
(+7%)
3-Yr Target (if PE normalizes)
(PE: 65â61)
PE COMPRESSION
$172.35
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 65.1, Growth: 27.9%)
$361.25
(+109%)
Base:
(SPY PE: 19.9, Growth: 27.9%)
$110.23
(-36%)
Bear:
(PE: 16.9, Growth: 27.9%)
$93.69
(-46%)
Share RGEN Analysis
Share this live RGEN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (RGEN)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 6, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish StockTwit user suggests that Regeneron Pharmaceuticals ($RGEN) is part of NWBO's and the UK's logistics plan, implying potential partnership opportunities.
Key Retail Themes:
partnership opportunities
logistics plan
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:53 AM ET
Data refreshes hourly during market hours. Next update: 3:53 AM
Data refreshes hourly during market hours. Next update: 3:53 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
STRONG BUY
34 analysts |
$486 | 40 SELL |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$82 | 44 HOLD |
|
WST
West Pharmaceutical ServâĻ |
STRONG BUY
16 analysts |
$471 | 50 HOLD |
|
RMD
ResMed Inc |
HOLD
20 analysts |
$264 | 58 HOLD |
|
MMSI
Merit Medical Systems Inc |
STRONG BUY
12 analysts |
$107 | 61 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive RGEN Research Pages
